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Abstract	  	  Antigenic	  stimulation	  via	  the	  B-­‐cell	  receptor	  (BCR)	  is	  a	  major	  driver	  of	  the	  proliferation	  and	   survival	   of	   chronic	   lymphocytic	   leukemia	   (CLL)	   cells.	   However,	   the	   precise	  mechanisms	  by	  which	  BCR	  stimulation	  leads	  to	  accumulation	  of	  malignant	  cells	  remain	  incompletely	   understood.	   Here,	   we	   investigated	   the	   ability	   of	   BCR	   stimulation	   to	  increase	  mRNA	  translation	  which	  can	  promote	  carcinogenesis	  by	  effects	  on	  both	  global	  mRNA	   translation	   and	   upregulated	   expression	   of	   specific	   oncoproteins.	   Re-­‐analysis	   of	  gene	   expression	   profiles	   revealed	   striking	   up-­‐regulation	   of	   pathways	   linked	   to	  mRNA	  translation	   both	   in	   CLL	   cells	   derived	   from	   lymph	   nodes,	   the	   major	   site	   of	   antigen	  stimulation	   in	   vivo,	   and	   following	   BCR	   stimulation	   in	   vitro.	   Anti-­‐IgM	   significantly	  increased	   mRNA	   translation	   in	   primary	   CLL	   cells,	   measured	   using	   bulk	   metabolic	  labeling	   and	   a	   novel	   flow	   cytometry	   assay	   to	   quantify	   responses	   at	   a	   single	   cell	   level.	  These	  translational	  responses	  were	  suppressed	  by	  inhibitors	  of	  BTK	  (ibrutinib)	  and	  SYK	  (tamatinib).	   Anti-­‐IgM-­‐induced	   mRNA	   translation	   was	   associated	   with	   increased	  expression	  of	  translation	  initiation	  factors	  eIF4A	  and	  eIF4GI,	  and	  reduced	  expression	  of	  the	  eIF4A	  inhibitor,	  PDCD4.	  Anti-­‐IgM	  also	  increased	  mRNA	  translation	  in	  normal	  blood	  B	   cells	   but	   without	   clear	   modulatory	   effects	   on	   these	   factors.	   Additionally	   anti-­‐IgM	  increased	   translation	   of	   mRNA	   encoding	  MYC,	   a	   major	   driver	   of	   disease	   progression.	  mRNA	  translation	  is	  likely	  to	  be	  an	  important	  mediator	  of	  the	  growth-­‐promoting	  effects	  of	   antigen	   stimulation	   acting,	   at	   least	   in	   part,	   via	   translational	   induction	   of	   MYC.	  Differences	   in	  mechanisms	   of	   translational	   regulation	   in	   CLL	   and	   normal	   B	   cells	  may	  provide	  opportunities	  for	  selective	  therapeutic	  attack.	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Key	  Points	  
	  BCR	  stimulation	  promotes	  mRNA	  translation	  in	  CLL	  cells,	   including	  of	  the	  oncoprotein,	  MYC,	  and	  is	  inhibited	  by	  ibrutinib	  or	  tamatinib.	  	  Differences	  in	  mechanisms	  of	  regulation	  of	  mRNA	  translation	  in	  CLL	  and	  normal	  blood	  B	  cells	  may	  highlight	  potential	  targets	  for	  therapeutic	  attack.	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INTRODUCTION	  	  B-­‐cell	  receptor	  (BCR)	  signaling	  is	  a	  major	  driver	  of	  malignant	  behavior	  in	  B-­‐cell	  cancers.	  BCR	   signaling	   has	   been	   relatively	  well	   studied	   in	   chronic	   lymphocytic	   leukemia	   (CLL)	  and	   the	   balance	   between	   antigen-­‐induced	   anergy	   and	   positive	   (growth-­‐promoting)	  signaling	  is	  a	  key	  determinant	  of	  variable	  clinical	  behavior.1	  CLL	  cell	  anergy	  is	  associated	  with	   reduced	   surface	   (s)IgM	   expression	   and	   signaling	   capacity.2	   It	   is	   observed	   at	  variable	  levels	  in	  all	  CLL	  samples,	  but	  is	  most	  prominent	  in	  samples	  expressing	  mutated	  
IGHV	   genes	   (M-­‐CLL)	   and	   is	   associated	   with	   indolent	   disease.	   By	   contrast,	   samples	  expressing	   unmutated	   IGHV	   genes	   (U-­‐CLL)	   tend	   to	   retain	   sIgM	   signaling	   capacity	   and	  positive	   signaling	   is	   associated	   with	   more	   progressive	   disease.	   These	   findings,	   and	  others,	  provided	  a	  strong	  impetus	  for	  clinical	  testing	  of	  new	  inhibitors	  of	  BCR-­‐associated	  signaling	   kinases.	   These	   have	   shown	   impressive	   responses	   and	   the	   BTK	   inhibitor,	  ibrutinib,	  is	  now	  approved	  for	  treatment	  of	  CLL	  and	  mantle	  cell	  lymphoma.3-­‐5	  	  	  Despite	   intense	   interest	   in	   the	   biology	   and	   drug-­‐targeting	   of	   BCR	   pathways	   in	   B-­‐cell	  malignancies,	   understanding	   the	   mechanisms	   which	   drive	   accumulation	   of	   malignant	  cells	  remains	  incomplete.	  One	  important	  response	  may	  be	  increased	  mRNA	  translation.	  mRNA	  translation	  is	  subject	  to	  tight	  control	  and	  recent	  studies	  performed	  using	  mouse	  fibroblasts	   indicated	   that	   mRNA	   translation	   regulation	   may	   play	   a	   similar	   role	   to	  transcription	  regulation	  in	  determining	  variation	  in	  protein	  expression.6,7	  	  	  Although	  relatively	  well	  studied	  in	  solid	  tumors,	  comparatively	  little	  is	  known	  about	  the	  control	   of	   mRNA	   translation	   in	   B-­‐cell	   malignancies,	   especially	   in	   primary	   malignant	  cells.	   Two	   recent	   studies	   identified	   increased	   expression/phosphorylation	   of	   specific	  mRNA	   translation	   initiation	   factors	   (eIFs),	   eIF4B	   and	   eIF4E,	   in	   diffuse	   large	   B-­‐cell	  lymphoma.8,9	   In	  CLL,	   stimulation	  of	  malignant	   cells	  by	  CD40L-­‐expressing	   stromal	   cells	  increased	  global	  mRNA	  translation	  and	  formation	  of	  the	  eIF4F	  complex	  which	  binds	  the	  5’CAP	   of	   mRNAs	   and	   enhances	   mRNA	   translation.10	   Previous	   comparisons	   of	   gene	  expression	   profiling	   (GEP)	   and	   proteomic	   analysis	   revealed	   differences	   in	   the	  transcriptomic	  and	  proteomic	  response	  following	  sIgM	  stimulation	  of	  CLL	  cells	  pointing	  to	   post-­‐transcriptional	   regulation.11,12	   However,	   whether	   mRNA	   translation	   is	  modulated	   by	   BCR	   signaling	   in	   CLL,	   where	   it	   is	   such	   a	   critical	   determinant	   of	   tumor	  behavior	  and	  target	  for	  therapy,	  is	  unknown.	  	  	  Increased	   mRNA	   translation	   plays	   important	   roles	   in	   carcinogenesis,	   via	   both	   global	  effects	  to	  support	  increased	  cell	  growth,	  and	  up-­‐regulation	  of	  specific	  oncoproteins.13,14	  
MYC	   RNA	   has	   a	   highly	   structured	   5’-­‐untranslated	   region	   and	   is	   one	   of	   a	   family	   of	  malignancy-­‐associated	   mRNAs	   for	   which	   translation	   is	   tightly	   dependent	   on	   eIF	  activity.15,16	   In	   our	   previous	   studies	   we	   demonstrated	   that	   MYC	   protein	   was	   induced	  following	   stimulation	  of	   sIgM	  of	  CLL	  cells	   in	  vitro	   and	   that	  MYC	   is	  highly	  expressed	   in	  proliferation	   centers	   in	   CLL	   lymph	  nodes	   (LN)17	  which	   are	   presumed	   to	   be	   the	  major	  sites	  of	  antigen-­‐induced	  cell	  division	  in	  vivo.18	  Therefore,	  we	  hypothesized	  that	  MYC	  may	  be	  an	  important	  target	  for	  translational	  regulation	  in	  CLL.	  	  In	   this	  work,	  we	   investigated	   effects	   of	   BCR	   stimulation	   on	  mRNA	   translation	   in	  vitro	  and	   in	   vivo.	   Bioinformatical	   analysis	   of	   GEP	   revealed	   that	   antigen	   stimulation	   of	   CLL	  cells	   in	  LN	   in	  vivo	  was	  associated	  with	  strong	   induction	  of	  multiple	  components	  of	   the	  mRNA	  translation	  machinery.	  Anti-­‐IgM	  stimulation	  of	  primary	  CLL	  cells	  in	  vitro	  resulted	  in	  increased	  mRNA	  translation,	  measured	  using	  bulk	  metabolic	  labeling	  and	  at	  a	  single	  cell	  level	  using	  a	  novel	  flow-­‐cytometry	  based	  assay.	  Anti-­‐IgM	  also	  resulted	  in	  increased	  translation	   of	   MYC	   mRNA	   and	   was	   associated	   with	   increased	   expression	   of	   the	  translation	   initiation	   factors	   eIF4GI	   and	   eIF4A.	   Furthermore	   ibrutinib	   and	   the	   SYK	  inhibitor,	   tamatinib,	   inhibited	   these	   responses.	   mRNA	   translation	   is	   likely	   to	   be	   an	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important	  mediator	  of	  growth-­‐promoting	  effects	  of	  antigen	  stimulation	  acting,	  at	  least	  in	  part,	  via	  translational	  induction	  of	  MYC.	  
	  
	  
MATERIALS	  AND	  METHODS	  
	  
Patients	  and	  cells	  for	  studies	  in	  vitro	  
	  Patients	   provided	   written	   informed	   consent	   in	   accordance	   with	   Ethics	   Committee	  approvals	   and	   the	  Declaration	   of	  Helsinki.	  Heparinized	  peripheral	   blood	  mononuclear	  cells	  (PBMCs)	  were	  obtained	  from	  patients	  attending	  clinics	  at	  the	  Southampton	  General	  Hospital	   or	   the	  Royal	   Berkshire	  Hospital	   (both	  UK)	   (Table	   S1).	   Diagnosis	   of	   CLL	  was	  according	   to	   the	   IWCLL-­‐NCI	   2008	   criteria19	   and	   the	   monoclonal	   B-­‐lymphocyte	  population	   in	   the	   peripheral	   blood	   had	   a	   typical	   IgM+IgD+	   CLL	   phenotype	   in	   all	  circumstances.20	  The	  vast	  majority	  of	  samples	  were	  obtained	  prior	  to	  treatment.	  Where	  treatment	  for	  CLL	  had	  taken	  place,	  this	  was	  at	  least	  6	  months	  prior	  to	  sample	  collection.	  
IGHV	  usage	  and	  homology	  to	  germline,	  expression	  of	  cell	  surface	  CD5,	  CD19,	  CD23	  and	  CD38,	  and	  ZAP70	  were	  determined	  as	  previously	  described.2,21	  sIgM	  signaling	  capacity	  was	  determined	  by	  measuring	  the	  percentage	  of	  cells	  with	   increased	   intracellular	  Ca2+	  following	  stimulation	  with	  soluble	  goat	  F(ab’)2	  anti-­‐IgM	  and	  using	  a	  cut-­‐off	  value	  of	  ≥5%	  responding	  cells	   to	  define	  samples	  as	  sIgM-­‐responsive	  as	  previously	  described.2	  PBMC	  samples	   from	   healthy	   donors	   were	   processed	   as	   previously	   described2	   and	  cryopreserved.	  B	  cells	  were	  isolated	  by	  negative	  selection	  using	  the	  human	  MACS	  B	  cell	  isolation	  kit	  II,	  according	  to	  manufacturer’s	  protocol	  (Miltenyi	  Biotec,	  Surrey,	  UK).	  	  CLL	   cells	   were	   either	   used	   directly	   (“fresh”)	   or	   following	   cryopreservation.	   When	  cryopreserved	  cells	  were	  used,	  recovered	  cells	  were	  rested	  for	  one	  hour	  at	  37°C	  prior	  to	  use.	  CLL	  cell	  viability	  determined	  by	   trypan	  blue	  exclusion	  was	  ≥90%	  and	   the	  median	  proportion	   of	   CD5+CD19+	   CLL	   cells	   was	   95%	   (range	   62-­‐99%).	   For	   sIg	   stimulation,	  samples	  were	  incubated	  with	  soluble	  or	  bead-­‐bound	  goat	  F(ab’)2	  anti-­‐human	  IgM,	  anti-­‐human	   IgD	   or	   control	   antibodies.22	   CpG-­‐ODN	   2006	   was	   from	   Source	   Bioscience	  (Nottingham,	   UK)	   and	   was	   used	   at	   7.5	   μg/ml.	   Ibrutinib	   and	   tamatinib	   were	   from	  SelleckChem	   (Suffolk,	   UK)	   and	  were	   used	   at	   10	  µM.	   Cells	  were	   pretreated	  with	   these	  compounds	  for	  1	  hour	  prior	  to	  stimulation.	  Cycloheximide	  (Sigma	  Chemicals,	  Poole,	  UK)	  was	  used	   as	   a	  positive	   control	   for	   inhibition	  of	  mRNA	   translation	   and	  was	  used	   at	   10	  
µg/ml	  in	  the	  final	  five	  minutes	  of	  incubation.	  For	  incubations	  greater	  than	  six	  hours,	  the	  caspase	   inhibitor	   Q-­‐VD-­‐OPh	   (5	   µM;	   Sigma)	   to	   minimize	   secondary	   events	   due	   to	  apoptosis.	  	  
	  
Protein	  synthesis	  assays	  
	  Metabolic	   labeling	   was	   performed	   using	   2x106	   cells	   per	   assay.	   Tran35S-­‐Label	   (MP	  Biomedicals,	   Illkirch,	  France)	  was	  added	  to	  the	  culture	  medium	  (0.37	  MBq/ml)	   for	  the	  final	  four	  hours	  of	  culture.	  Cells	  were	  collected	  by	  centrifugation	  and	  washed	  in	  ice-­‐cold	  phosphate	  buffered	  saline	  (PBS).	  Cells	  were	  resuspended	  in	  water	  containing	  10	  mg/ml	  L-­‐cysteine	   and	   10	   mg/ml	   L-­‐methionine,	   and	   subjected	   to	   two	   freeze-­‐thaw	   cycles.	  Lysates	   were	   then	   incubated	   at	   37oC	   for	   15	   minutes	   and	   clarified	   by	   centrifugation.	  Lysates	   were	   applied	   to	   Whatmann	   filter	   discs	   (GE	   Healthcare,	   Amersham,	   UK)	   and	  allowed	   to	   air	   dry.	   Bound	   proteins	   were	   precipitated	   by	   addition	   of	   10%	   (w/v)	  trichloroacetic	   acid	   (TCA;	   Sigma	   Chemicals).	   Boiling	   5%	   (w/v)	   TCA	  was	   added	   to	   the	  filter	   discs	   before	  washing	   in	   100%	   (v/v)	   ethanol	   and	   100%	   (v/v)	   acetone.	   The	   filter	  discs	  were	  air-­‐dried	  prior	   to	  scintillation	  counting	  using	  OptiScint	   ‘HiSafe’	   scintillation	  fluid	   (PerkinElmer,	   Cambridgeshire,	   UK)	   and	   a	   WALLAC	   1409	   liquid	   scintillation	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Gene	   expression	   network	   analysis	   reveals	   increased	   mRNA	   translation	   as	   a	   prominent	  
response	  to	  antigen	  engagement	  in	  vivo	  
	  We	   used	   unsupervised	   consensus	   weighted	   gene	   co-­‐expression	   network	   analysis	  (WGCNA)23	   of	   two	   published	   GEP	   datasets	   to	   identify	   growth-­‐promoting	   pathways	  activated	   following	  antigen	   stimulation	  of	  CLL	   cells	   in	  vivo.	  The	  datasets	  were	  derived	  from	  the	  study	  of	  Herishanu	  et	  al	  which	  compared	  gene	  expression	  of	  matched	  samples	  of	  CLL	  cells	  derived	  from	  LN,	  blood	  and	  bone	  marrow	  (BM)18	  and	  the	  study	  of	  Vallat	  et	  al	  which	  investigated	  effects	  of	  anti-­‐IgM	  on	  CLL	  cell	  gene	  expression	  in	  vitro.11	  For	  further	  details	  of	  WGCNA,	  please	  see	  Supplementary	  material.	  	  WGCNA	  identified	  14	  modules	  of	  genes	  which	  had	  similar	  patterns	  of	  expression	  across	  the	  11	  conditions	   comprising	   the	   two	  data	   sets	   (Figure	   S1A,B).	  The	  blue	  module	  was	  particularly	   interesting	   since	   expression	   of	   this	   module’s	   eigengene	   (the	   gene	  considered	   to	   be	   the	   first	   principal	   component)23	   correlated	   very	   strongly	   with	   both	  anti-­‐IgM	   stimulation	   (especially	   at	   210	   and	   390	   minutes)	   and	   LN	   derivation	   (Figure	  
1A).	  There	  was	  also	  a	  very	  strong	  positive	  correlation	  between	  the	  kME	  (a	  connectivity	  measure	  which	  reflects	  the	  “centrality”	  of	  each	  gene	  to	  the	  module)	  of	  individual	  genes	  comprising	   the	   blue	  module	   and	   variation	   in	   gene	   expression	   between	   LN	   and	   other	  tissues,	   and	   following	   anti-­‐IgM	   stimulation	   in	   vitro	   (Figure	   1B).	   Overall,	   WGCNA	  identified	  a	  module	  of	  genes	  (the	  blue	  module)	  with	  very	  strong	  co-­‐ordinate	  regulation	  
in	   vitro	   following	   sIgM	   stimulation,	   and	   in	   LN	   samples	   compared	   to	   other	   tissues,	  indicating	   that	   this	  module	   comprises	   genes	  most	   strongly	   induced	   following	   antigen	  engagement	  in	  vivo.	  	  To	   probe	   the	   biological	   pathways	   represented	   by	   the	   blue	   module,	   we	   identified	  enriched	   gene	   ontology	   terms	   and	   organized	   these	   into	   a	   “TreeMap”	   using	   REVIGO	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(Figure	  1C).24	  Enriched	  terms	  included	  “regulation	  of	  cell	  cycle”	  consistent	  with	  the	  idea	  that	   the	   LN	   is	   the	   major	   site	   for	   CLL	   cell	   proliferation	   in	   vivo.	   However,	   the	   most	  commonly	   over-­‐represented	   ontologies	   were	   associated	   with	   stress	   responses,	  including	   the	   endoplasmic	   reticulum-­‐located	   unfolded	   protein	   response	   (UPR),	  metabolism	  and	  mRNA	  translation.	  	  	  We	  performed	  a	   similar	   analysis	  using	   Ingenuity	  Pathway	  Analysis	   (IPA)	   (Figure	   S2).	  This	   revealed	   that	   the	   blue	   module	   comprised	   networks	   linked	   to	   protein	   synthesis,	  energy	   production	   and	   amino-­‐acid/nucleic	   acid	   metabolism.	   For	   example,	   network	   3	  comprised	  multiple	   eIFs	   (eg,	   eIF3B,	   eIF4A1,	   eIF4E)	   and	   factors	   involved	   in	   ribosome	  biogenesis	  (eg,	  NOLC1,	  NOP10).	  IPA	  “upstream	  analysis”	  identified	  MYC	  as	  the	  strongest	  driver	  of	  the	  blue	  module	  (P=1.91x10-­‐30)	  and	  the	  highest	  scoring	  network	  (network	  1)	  was	   a	   MYC-­‐centered	   network	   with	   linkage	   to	   metabolism	   (eg,	   LDHA,	   ENO1,	   MCT1,	  IDH3A)	  and	  mRNA	  translation	  (eg,	  ABCE1,	  NPM1),	  including	  DDX21,	  recently	  identified	  as	  central	  coordinator	  of	  ribosome	  biogenesis.25	  	  Finally,	   we	   examined	   the	   functions	   of	   individual	   genes	   comprising	   the	   blue	   module	  (Table	   S2).	   Nearly	   half	   of	   the	   50	   highest	   kME	   genes	   with	   known	   function	   had	  established	  or	  potential	   links	  to	  protein	  synthesis,	   including	  factors	  involved	  in	  amino-­‐acid	   transport	   (SLC3A2,	   SLC7A5),	   ribosome	   biosynthesis	   (BYSL,	   RRP12,	   RPF2)	   and	  translation	  initiation/termination	  (eIF3B,	  ABCE1	  and	  BZW2).	  	  Overall,	   network	   analysis	   revealed	   prominent	   regulation	   of	   biosynthetic	   and	   stress	  response	  pathways	  following	  BCR	  engagement	  in	  vivo.	  Regulation	  of	  the	  UPR	  and	  MYC	  is	  consistent	  with	  our	  previous	  reports	  demonstrating	  induction	  of	  a	  partial	  UPR	  and	  MYC	  in	  CLL	  cells	  following	  sIgM	  stimulation	   in	  vitro,	  and	  in	  CLL	  cells	  in	  LN.17,26	  However,	  an	  important	  new	   finding	  was	   the	  particularly	  strong	  regulation	  of	  genes	  associated	  with	  mRNA	   translation.	   Since	   network	   analysis	   suggested	   a	   prominent	   role	   for	   increased	  mRNA	   translation	   following	   engagement	   of	   the	   BCR	   of	   CLL	   cells	   in	   vivo	   we	   next	  investigated	  its	  potential	  regulation	  by	  anti-­‐IgM	  in	  vitro.	  	  	  
sIgM	   stimulation	   increases	   global	  mRNA	   translation	   in	   signal-­‐responsive	  CLL	   samples	   in	  
vitro	  	  We	  used	  metabolic	  labeling	  to	  quantify	  effects	  of	  sIgM	  stimulation	  on	  mRNA	  translation	  in	  CLL	  samples.	   sIgM	  signaling	  capacity	   is	  variable	   in	  CLL	  and	  we	   therefore	  selected	  a	  cohort	  of	  samples	  (n=21),	  all	  classified	  as	  sIgM	  signal	  competent	  based	  on	  Ca2+	  response	  following	   soluble	   anti-­‐IgM	   stimulation.2	   This	   cohort	   comprised	   U-­‐CLL	   samples	   and	  representatives	  of	  the	  smaller	  proportion	  of	  signal-­‐responsive	  M-­‐CLL.	  Effects	  on	  mRNA	  translation	  were	  analyzed	  using	  a	  bead-­‐bound	  form	  of	  anti-­‐IgM	  which	  induces	  relatively	  strong	   signaling	   responses	   compared	   to	   soluble	   antibody,22,26	   and	  with	   “fresh”	   (n=11)	  and	  cryopreserved	  (n=10)	  samples	   to	  control	   for	  potential	  effects	  of	  storage.	  CLL	  cells	  undergo	   variable	   levels	   of	   spontaneous	   apoptosis	   in	   vitro	   so	   cells	   were	   additionally	  treated	  with	  a	  caspase	  inhibitor	  (Q-­‐VD-­‐OPh)	  to	  minimize	  potentially	  confounding	  effects	  of	  apoptosis.	  	  Metabolic	  labeling	  demonstrated	  that	  anti-­‐IgM	  beads	  increased	  mRNA	  translation	  in	  all	  samples	   (Figure	   2A,	  Figure	   S3A).	  As	  expected	   for	   this	  cohort	  selected	  on	   the	  basis	  of	  retained	  signal-­‐responsiveness,	  the	  fold	  increase	  in	  anti-­‐IgM-­‐induced	  metabolic	  labeling	  was	   not	   significantly	   different	   between	   U-­‐CLL	   and	   M-­‐CLL	   (Figure	   S3B).	   Anti-­‐IgM-­‐responses	   were	   also	   not	   significantly	   influenced	   by	   cryopreservation	   (Figure	   S3C).	  Therefore,	  all	  subsequent	  experiments	  were	  performed	  using	  frozen	  samples.	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We	   also	   investigated	   anti-­‐IgM-­‐induced	   mRNA	   translation	   in	   four	   additional	   M-­‐CLL	  samples	   which	   were	   considered	   as	   sIgM	   non-­‐responsive	   based	   on	   Ca2+	   mobilization	  analysis.2	  Anti-­‐IgM	  beads	  increased	  metabolic	  labeling	  in	  these	  samples	  but	  the	  overall	  response	   (~2-­‐fold	   mean	   induction)	   was	   clearly	   lower	   than	   for	   signaling	   responsive	  samples	  (~6-­‐fold)	  (Figure	  S3D).	  	  Finally,	   we	   compared	   response	   to	   bead-­‐bound	   anti-­‐IgM	   and	   anti-­‐IgD	   in	   17	   of	   the	   21	  samples	  initially	  analyzed	  for	  anti-­‐IgM	  responses.	  Anti-­‐IgD	  enhanced	  mRNA	  translation,	  however,	  stimulatory	  effects	  of	  anti-­‐IgD	  (~2-­‐fold)	  were	  significantly	  reduced	  compared	  to	  anti-­‐IgM	  (~6-­‐fold;	  Figure	  S4).	  	  	  
Effect	  of	  tamatinib	  and	  ibrutinib	  on	  anti-­‐IgM-­‐induced	  mRNA	  translation	  	  We	  used	  tamatinib	  and	   ibrutinib	   to	   investigate	  potential	  roles	  of	  SYK	  and	  BTK	   in	  anti-­‐IgM-­‐induced	  mRNA	  translation.	  SYK	   is	  one	  of	   the	   first	  kinases	  activated	   following	  BCR	  stimulation	   and	   co-­‐ordinates	   activation	   of	   downstream	   signaling	   within	   the	  signalosome,	   including	   BTK.	   Tamatinib	   and	   ibrutinib	   were	   used	   at	   10	   μM,	   based	   on	  previous	   publications	   and	   our	   own	  pilot	   studies.27	   Inhibitory	   effects	   of	   ibrutinib	  were	  partial,	   decreasing	   anti-­‐IgM-­‐induced	   metabolic	   labeling	   by	   ~60%	   whereas	   tamatinib	  completely	  blocked	  the	  response	  (Figure	  2B).	  Tamatinib	  also	  modestly	  reduced	  “basal”	  protein	  synthesis	  in	  cells	  treated	  with	  control	  beads.	  Analysis	  of	  cell	  death	  demonstrated	  that	   tamatinib	   and	   ibrutinib	   did	   not	   significantly	   reduce	   cell	   viability	   under	   our	  experimental	   conditions	   where	   Q-­‐VD-­‐OPh	   was	   added	   to	   decrease	   caspase	   activation	  (Figure	  S5).	  	  	  Parallel	   analysis	   of	   signaling	   confirmed	   inhibition	   of	   anti-­‐IgM-­‐induced	   ERK1/2	  phosphorylation	  in	  these	  experiments	  (Figure	  2C,D).	  In	  addition,	  ibrutinib	  or	  tamatinib	  effectively	   inhibited	  anti-­‐IgM-­‐induced	  phosphorylation	  of	  p70S6K,	   a	  positive	   regulator	  of	   mRNA	   translation	   which	   is	   phosphorylated	   by	   mTORC1	   downstream	   of	   the	  PI3KàAKT	  pathway	   (Figure	   2C,D).28	  Consistent	  with	   the	   longer	  duration	  of	   signaling	  induced	   by	   bead-­‐bound	   anti-­‐IgM,	   increased	   phosphorylation	   of	   ERK1/2	   and	   p70S6K	  was	  maintained	  at	  6	  hours	  post-­‐stimulation	  (data	  not	  shown).	  	  	  
Single	  cell	  analysis	  of	  mRNA	  translation	  	  We	   extended	   our	   analysis	   using	   flow	   cytometry	   to	   quantify	   mRNA	   translation	   on	   a	  single	  cell	  basis.29	  In	  this	  assay,	  cells	  were	  incubated	  with	  a	  puromycin	  analogue	  (OPP)	  which	  is	  incorporated	  into	  nascent	  polypeptide	  chains	  and	  then	  fluorescently	  labeled	  via	  “Click	  Chemistry”	  (Figure	  3A).	  We	  gated	  on	  viable	  cells	  and	  OPP-­‐labeling	  was	  combined	  with	  staining	  with	  anti-­‐CD19	  and	  anti-­‐CD5	  antibodies	  to	  enable	  separate	  quantification	  of	   protein	   synthesis	   in	   CLL	   cells	   and	   non-­‐malignant	   T	   cells	  which	   are	   also	   present	   at	  variable	  levels	  in	  PBMC	  samples	  from	  CLL	  patients	  (Figure	  S6).	  	  In	  CLL	  cells,	  anti-­‐IgM	  beads	  significantly	  increased	  OPP-­‐labeling	  by	  ~3-­‐fold	  on	  average	  (Figure	   3B).	   We	   also	   tested	   responses	   to	   CpG-­‐ODN	   which	   is	   a	   relatively	   strong	  stimulating	   agent	   for	   CLL	   cells.30	   CpG-­‐ODN	   increased	  OPP-­‐labeling	   to	   a	   greater	   extent	  than	  anti-­‐IgM	  (~8-­‐fold	  on	  average).	  We	  used	  a	  “B-­‐cell	  specific”	  CpG-­‐ODN	  (2006)	  in	  these	  experiments	  and,	  as	  expected,	  neither	  CpG-­‐ODN,	  or	  anti-­‐IgM,	  increased	  OPP-­‐labeling	  in	  T	  cells	  (Figure	  3B)	  demonstrating	  specificity	  of	  the	  response.31	  	  	  Similar	   to	   metabolic	   labeling,	   OPP-­‐labeling	   in	   CLL	   cells	   was	   significantly	   reduced	   by	  ibrutinib	  and	  tamatinib	  (Figure	  3D).	  Tamatinib	  reduced	  anti-­‐IgM-­‐induced	  OPP-­‐labeling	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below	  the	  level	  of	  unstimulated	  cells.	  Effects	  of	  ibrutinib	  were	  partial	  (~50%	  reduction).	  The	  drugs	  had	  no	  significant	  effect	  on	  OPP-­‐labeling	  in	  T	  cells	  (Figure	  3C).	  Analysis	  using	  OPP-­‐labeling	   confirms	   that	   sIgM	   stimulation	   of	   CLL	   cells	   increases	   mRNA	   translation	  and	  demonstrates	  that	  this	  occurs	  within	  the	  malignant	  clone.	  	  	  We	  also	  used	  the	  OPP-­‐labeling	  assay	  to	  investigate	  the	  effects	  of	  varying	  BCR	  signaling	  strength	  by	   comparing	   responses	   to	  anti-­‐IgM	  beads	  and	  soluble	  anti-­‐IgM.	   In	  CLL	  cells,	  responses	   to	   soluble	   anti-­‐IgM	   are	   generally	  weak	   and	   short-­‐lived,	   even	   in	   responsive	  samples.	   Soluble	   anti-­‐IgM	   significantly	   increased	   mRNA	   translation,	   but	   to	   a	   lower	  extent	   than	  bead-­‐bound	  antibody	  (Figure	   3B).	  Therefore,	   increased	  mRNA	  translation	  in	   CLL	   cells	   is	   sensitive	   to	   signal	   strength	   and	   efficient	   activation	   requires	  protracted/stronger	  sIgM-­‐induced	  signaling.	  	  	  
Regulation	  of	  eIFs	  and	  PDCD4	  in	  CLL	  and	  normal	  B	  cells	  
	  We	   investigated	   the	  mechanisms	   that	  mediated	  anti-­‐IgM-­‐induced	  mRNA	   translation	   in	  CLL	   cells	   by	   analyzing	   expression	   of	   key	   mRNA	   translation	   initiation	   factors.	   Direct	  analysis	  of	  the	  Vallat	  dataset11	  confirmed	  that	  anti-­‐IgM	  increased	  expression	  of	  eIF4A1,	  
eIF4G1	  and	  eIF3b	  mRNAs	  (Figure	  S7),	  as	  initially	  revealed	  by	  network	  analysis	  (Figure	  
S2).	  Immunoblot	  analysis	  demonstrated	  that	  bead-­‐bound	  anti-­‐IgM	  increased	  expression	  of	   eIF4A	   and	   eIF4GI	   at	   the	   protein	   level.	   However,	   we	   did	   not	   detect	   any	   changes	   in	  eIF3b	   protein	   expression.	   Anti-­‐IgM	   also	   significantly	   down-­‐regulated	   expression	   of	  PDCD4,	  a	  negative	  regulator	  of	  eIF4A	  (Figure	  4A,B)32	  although	  there	  was	  no	  change	  in	  
PDCD4	  mRNA	  expression	  following	  anti-­‐IgM	  treatment	  (Figure	  S7).	  	  We	   also	   investigated	  mRNA	   translation	   and	   protein	  modulation	   in	   normal	   cells	   using	  peripheral	   B	   cells	   from	   independent	   donors	   as	   a	   direct	   comparator	   for	   CLL	   blood	  samples.	  All	   donors	   had	   a	   high	  proportion	   of	   IgM-­‐expressing	  CD19+	   cells	   (mean	  84%;	  
Figure	   S8A).	   Anti-­‐IgM	   increased	   OPP-­‐labeling	   of	   normal	   (CD19+CD5-­‐)	   B	   cells	   in	   all	  samples,	   with	   no	   effect	   on	   CD19-­‐CD5+	   T	   cells	   (Figure	   4C).	   In	   contrast	   to	   CLL	   cells,	  soluble	  anti-­‐IgM	  was	  an	  effective	  inducer	  of	  mRNA	  translation	  in	  normal	  B	  cells.	  In	  fact,	  response	  to	  soluble	  anti-­‐IgM	  appeared	  to	  be	  greater	  than	  bead-­‐bound	  anti-­‐IgM	  in	  these	  cells.	  	  To	   investigate	   protein	   expression,	   we	   isolated	   CD19+	   B	   cells	   (>99%	   purity)	   and	  stimulated	  these	  cells	  with	  soluble	  anti-­‐IgM.	  Soluble	  anti-­‐IgM	  was	  used	  since	  it	  appeared	  to	  exert	  the	  strongest	  effect	  on	  OPP-­‐labeling	  in	  normal	  B	  cells	  (Figure	  4C).	  There	  was	  a	  trend	   towards	   increased	   eIF4GI	   and	   decreased	   PDCD4	   expression	   in	   stimulated	   cells	  (Figure	  4D,E).	  However,	  eIF4A	  was	  clearly	  unchanged	  and	  differences	  in	  expression	  of	  eIF4GI	   and	   PDCD4	   were	   not	   significant.	   Analysis	   of	   phospho-­‐ERK1/2	   and	   phospho-­‐p70S6K	   confirmed	   activation	   of	   signaling	   pathways	   (Figure	   S8B).	   Thus,	   sIgM	  stimulation	  increases	  mRNA	  translation	  in	  both	  normal	  B	  cells	  and	  CLL	  cells.	  However,	  responses	   in	   CLL	   cells	   may	   involve	   a	   broader	   reprogramming	   of	   the	   translation	  machinery	  compared	  to	  normal	  B	  cells.	  	  	  
Increased	   mRNA	   translation	   contributes	   to	   increased	   MYC	   expression	   following	   sIgM	  
stimulation	  	  We	   investigated	   the	   effect	   of	   bead-­‐bound	   anti-­‐IgM	   on	   translation	   of	   mRNA	   encoding	  MYC.	  Analysis	   of	  MYC	  mRNA	   translation	  was	  based	  on	  polysome	  profiling.	  Analysis	   of	  sucrose	  gradients	   revealed	   that	   the	  overall	   abundance	  of	  polysome-­‐associated	  mRNAs	  was	  very	  low	  in	  un-­‐stimulated	  CLL	  cells	  (Figure	  S9).	  Consistent	  with	  metabolic	  labeling	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and	  OPP	  assays,	  there	  was	  an	  increase	  in	  the	  abundance	  of	  polysome-­‐associated	  mRNAs	  following	   sIgM	   stimulation	   although	   this	   was	   modest	   and	   not	   clearly	   observed	   in	   all	  samples.	  	  To	  analyze	  MYC	  expression,	  we	  quantified	  MYC	  mRNA	   in	   fractions	   from	   the	  polysome	  profiles	   using	   Q-­‐PCR.	   Consistent	   with	   previous	   studies	   demonstrating	   transcriptional	  increases11,17,	  anti-­‐IgM	  increased	  the	  total	  amount	  of	  MYC	  mRNA	  detected	  in	  all	  fractions	  (compare	  first	  two	  bars	  in	  Figure	  5A).	  There	  was	  also	  a	  clear	  increase	  in	  the	  amount	  of	  
MYC	  mRNA	  present	   in	  polysome	  associated	   fractions	  demonstrating	   that	  anti-­‐IgM	  also	  increased	   MYC	   mRNA	   translation.	   This	   was	   observed	   regardless	   of	   whether	   we	  determined	  the	  absolute	  amount	  of	  MYC	  mRNA	  in	  polysome	  fractions	  (Figure	  5B)	  or	  the	  proportion	  of	  polysome-­‐associated	  MYC	  mRNA	  (Figure	  5C)	  which	  measures	  translation	  changes,	   independent	   of	   changes	   in	   the	   overall	   levels	   of	  MYC	   mRNA.	   Consistent	   with	  increased	   MYC	   translation	   and	   transcription,	   anti-­‐IgM	   significantly	   increased	   MYC	  protein	   expression	   (Figure	   5D,E).	   Ibrutinib	   and	   tamatinib	   significantly	   reduced	   anti-­‐IgM-­‐induced	  MYC	  mRNA	  translation	  (and	  transcription)	  (Figure	  5A-­‐C).	  Similar	  to	  effects	  on	   overall	  mRNA	   translation,	   effects	   of	   ibrutinib	  were	   partial,	  whereas	   tamatinib	   had	  more	  pronounced	  effects.	  The	  compounds	  also	  significantly	   inhibited	  anti-­‐IgM-­‐induced	  MYC	  protein	  expression	  (Figure	  5D,E).	  	  
	  
DISCUSSION	  	  mRNA	  translation	  is	  a	  key	  cancer-­‐associated	  pathway	  but	  has	  not	  been	  well	  studied	  in	  B-­‐cell	  malignancies.	  Here	  we	  show	  for	  the	  first	  time	  that	  stimulation	  of	  the	  BCR	  of	  CLL	  cells	   promotes	   mRNA	   translation	   in	   vitro	   and	   in	   vivo.	   Increased	   mRNA	   translation	   is	  likely	  to	  contribute	  to	  antigen-­‐induced	  CLL	  cell	  accumulation	  via	  effects	  on	  both	  global	  mRNA	   translation	   and	   expression	   of	   specific	   oncoproteins,	   including	  MYC.	   This	   study	  therefore	  reveals	  an	  important	  new	  pro-­‐malignancy	  pathway	  operating	  downstream	  of	  the	  BCR	  in	  CLL	  cells	  with	  clear	  relevance	  for	  drug	  targeting.	  	  We	   used	   an	   integrated	   bioinformatical	   approach	   to	   probe	   transcriptional	   signatures	  induced	   by	   antigen	   engagement	   of	   CLL	   cells	   in	   LN	   in	   vivo.	   Previous	   analysis	   of	   cells	  isolated	   from	   different	   compartments	   highlighted	   BCR	   and	   NF-­‐κB	   signaling,	   and	  modulation	   of	   cell	   cycle,	   as	   key	   pathways	   activated	   in	   LN.18	   As	   expected,	   there	   was	  overlap	   between	   the	   genes	   and	   pathways	   identified	   in	   our	   analysis	   and	   this	   previous	  work,	   including	   identification	   of	   MYC	   as	   a	   key	   driver	   of	   transcriptional	   responses.	  However,	   the	   important	   new	   finding	   from	   our	   analysis	   was	   the	   extent	   to	   which	   the	  response	  in	  vivo	  was	  dominated	  by	  genes	  linked	  to	  mRNA	  translation.	  	  	  Our	  studies	   in	  vitro	   focused	  on	  signal-­‐responsive	  samples,	  demonstrating	  that	  anti-­‐IgM	  increased	   mRNA	   translation	   in	   samples	   from	   both	   the	   U-­‐CLL	   and	   M-­‐CLL	   subsets.	  Although	  analysis	  was	  restricted	  to	  a	  few	  samples,	  anti-­‐IgM-­‐induced	  mRNA	  translation	  was	  substantially	  lower	  in	  M-­‐CLL	  samples	  that	  were	  considered	  non-­‐responsive	  on	  the	  basis	  of	  calcium	  mobilization.	  Similar	  to	  other	  signaling	  readouts,26	  mRNA	  translation	  in	  CLL	  cells	  was	  also	   lower	  in	  cells	  treated	  with	  soluble	  anti-­‐IgM.	  Moreover,	  responses	  to	  bead-­‐bound	   anti-­‐IgD	  were	   clearly	   reduced	   compared	   to	   anti-­‐IgM,	   consistent	  with	   our	  previous	   study	   demonstrating	   that	   although	   most	   CLL	   samples	   retain	   initial	   sIgD	  signaling	  responsiveness,	  anti-­‐IgD	   fails	   to	  effectively	   induce	  MYC	  expression.17	  Further	  studies	  are	  required	  to	  probe	  the	  relationship	  between	  increased	  mRNA	  translation	  and	  other	  sIgM	  signaling	  responses,	  but	  increased	  mRNA	  translation	  is	  likely	  to	  be	  part	  of	  a	  constellation	   of	   responses	   co-­‐regulated	   downstream	   of	   sIgM	   in	   signal-­‐responsive	  samples	  and	  sensitive	  to	  signal	  strength.1	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In	  addition	  to	  analyzing	  global	  mRNA	  translation,	  we	  also	  showed	  for	  the	  first	  time	  that	  	  MYC	   is	   a	   target	   for	   translational	   regulation	   in	   CLL	   following	   sIgM	   stimulation.	   We	  confirmed	  induction	  of	  MYC	  mRNA	  following	  sIgM	  stimulation,11,17	  but	  also	  showed	  that	  increased	  mRNA	   translation	   contributed	   to	   induction	   of	  MYC	  protein.	   Interestingly,	   in	  addition	  to	  being	  translationally	  regulated,	  MYC	  may	  also	  play	  a	  role	  in	  up-­‐regulation	  of	  translation	  as	  part	  of	  a	  positive	  feedback	  loop.16	  For	  example,	  MYC	  is	  a	  major	  regulator	  of	  ribosome	  biosynthesis33	  and	  can	  also	  induce	  eIF	  expression.34,35	  MYC-­‐mediated	  effects	  could	   also	   involve	   translational	   modulation	   via	   miRNAs;	   BCR	   stimulation	   modulates	  miRNA	  expression	  in	  CLL	  cells	  and	  MYC	  is	  a	  master	  regulator	  of	  miRNA	  networks.36,37	  	  Results	   with	   inhibitors	   are	   consistent	   with	   a	   pivotal	   role	   for	   SYK	   in	   mediating	  translational	  induction	  downstream	  of	  the	  BCR	  since	  tamatinib	  very	  effectively	  blocked	  anti-­‐IgM-­‐induced	   mRNA	   translation,	   including	   of	  MYC	   mRNA.	   Responses	   to	   ibrutinib	  were	  partial,	  perhaps	  indicating	  bifurcation	  of	  translation-­‐promoting	  pathways	  between	  SYK	   and	   BTK.	   However,	   these	   results	   should	   be	   interpreted	  with	   caution	   and	   further	  work	   is	   required	   to	   “map”	   translational	   regulation	   signaling	   pathways.	   For	   example,	  tamatinib	   and	   ibrutinib	   may	   have	   “off-­‐target”	   effects.38,39	   Although	   in	   line	   with	   other	  studies,	   the	   drug	   concentrations	   used	   for	   our	   studies	   exceed	   plasma	   concentrations	  following	  administration	  to	  patients.3,40	  Thus,	  further	  work	  is	  also	  required	  to	  determine	  whether	  ibrutinib,	  for	  example,	  results	  in	  decreased	  mRNA	  translation	  in	  patients.	  	  	  It	  was	  particularly	   interesting	   to	  note	   that	   tamatinib	  was	  a	  more	  effective	   inhibitor	  of	  mRNA	   translational	   responses,	   whereas	   ibrutinib	   appears	   to	   yield	   superior	   clinical	  responses	  in	  patients.	  There	  are,	  of	  course,	  many	  potential	  explanations	  for	  the	  apparent	  inconsistency.	  One	  possibility	   is	   that	  on-­‐target	   inhibition	  of	  SYK	   in	  other	   cell	   types,	  or	  off-­‐target	  effects,	  limit	  clinical	  effectiveness	  of	  fostamatinib	  (the	  prodrug	  for	  tamatinib).	  Therefore,	  concentrations	  for	  effective	   inhibition	  of	  BCR	  signaling	  in	  CLL	  cells	  may	  not	  be	  achieved	  or	  sustained	   in	  patients.	  Alternately,	   the	  more	  dramatic	  clinical	  responses	  to	  ibrutinib	  may	  be	  driven	  by	  its	  effects	  on	  other	  pathways	  independent	  of	  the	  BCR,	  on	  other	   cell	   types	   which	   express	   BTK,	   or	   may	   be	   BTK-­‐independent.38,39,41-­‐43	   Definitive	  answers	   will	   require	   clinical	   evaluation	   of	   additional	   (especially	   more	   selective)	  inhibitors	   to	   determine	   whether	   this	   is	   a	   class	   effect,	   and	   parallel	  pharmacokinetic/pharmacodynamic	   analysis	   to	   define	   the	   relationship	   between	  molecular	  responses	  in	  vitro	  and	  clinical	  outcome.	  	  We	   investigated	   the	   mechanisms	   by	   which	   sIgM	   stimulation	   caused	   increased	   mRNA	  translation	   in	   CLL	   and	   normal	   B	   cells.	   A	   recent	   study	   demonstrated	   that	   anti-­‐IgM-­‐induced	   translation	   in	   normal	   human	   splenic	   B	   cells	   was	   associated	   with	   decreased	  expression	  of	  the	  eIF4A	  inhibitor	  PDCD4,	  and	  increased	  eIF4A	  and	  eIF4E	  5’CAP	  complex	  formation,	   but	  without	   changes	   in	   the	   overall	   expression	   of	   these	   eIFs.44	   In	   our	   study	  using	  normal	  blood	  B	  cells,	  increased	  mRNA	  translation	  occurred	  without	  clear	  changes	  in	  expression	  of	  eIF4A,	  PDCD4	  or	  eIF4GI.	  By	  contrast,	   in	  CLL	  cells,	  anti-­‐IgM	  resulted	  in	  clear	   increases	   in	   expression	   of	   eIF4A	   and	   eIF4GI,	   as	   well	   as	   decreased	   PDCD4	  (confirming	   previous	   observations	   in	   CLL	   cells	   by	   Perrot	   et	   al).12	   Thus,	   although	   BCR	  stimulation	  increased	  mRNA	  translation	  in	  both	  CLL	  and	  normal	  B	  cells,	  mechanisms	  of	  regulation	  appear	  to	  differ	  between	  these	  cell	  types	  with	  CLL	  responses	  associated	  with	  broader	  modulation	  of	  the	  translation	  machinery.	  	  In	   conclusion,	   BCR	   stimulation	   of	   CLL	   cells	   triggers	   a	   profound	   increase	   in	   mRNA	  translation	   in	   vitro	   and	   in	   vivo.	   This	   response	   is	   likely	   to	   be	   important	   for	   cell	  accumulation	   (via	   effects	   on	   both	   global	   mRNA	   translation	   and	   expression	   of	  oncoproteins)	  and	  its	  inhibition	  might	  contribute	  to	  clinical	  effects	  of	  kinase	  inhibitors,	  such	  as	   ibrutinib.	  Direct	   inhibition	  of	  mRNA	  translation	   is	  an	  exciting	  area	   for	   therapy	  for	  hematological	  malignancies	  with	  compounds	  such	  ribavirin,	  homoharringtonine	  and	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silvestrol	   undergoing	   assessment	   in	   multiple	   clinical	   trials.	   Activity	   has	   focused	   on	  myeloid	  leukemia,	  whereas	  our	  study	  suggests	  that	  such	  agents	  could	  also	  be	  useful	   in	  B-­‐cell	   lymphoma.	   In	   fact,	   various	  mRNA	   translation	   inhibitors	   accelerate	   apoptosis	   of	  CLL	   cells	   in	   vitro10,45,46.	   Recent	   studies	   in	   colorectal	   cancer	   demonstrate	   that	   targeted	  inhibition	   of	   mRNA	   translation	   is	   an	   effective	   strategy	   to	   counter	   MYC-­‐driven	  tumorigenesis	   in	   vivo,	   whereas	   inhibition	   of	   upstream	   signaling	   was	   confounded	   by	  complex	   compensatory	   cross-­‐talk.47	   Thus,	   targeted	   inhibition	   of	   mRNA	   translation	   in	  CLL	  may	  also	  be	  an	  effective	  strategy	  to	  counter	  MYC	  function.	  Importantly,	  the	  different	  mechanisms	   of	   translational	   regulation	   downstream	   of	   the	   BCR	   in	   CLL	   and	   normal	   B	  cells	  may	  provide	  opportunities	  for	  therapeutic	  attack.	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Figure	  1.	  Analysis	  of	  gene	  expression	  networks	  using	  WGCNA	  (A)	   Correlations	   between	   consensus	   modules	   identified	   by	   WGCNA	   and	   specific	  experimental	   conditions.	   The	   y-­‐axis	   shows	   the	   14	   consensus	   modules	   which	   were	  randomly	   assigned	   different	   colors	   for	   identification	   and	   the	   x-­‐axis	   shows	   the	   11	  experimental	   conditions	   defined	  within	   the	   two	  GEP	   studies.11,18	   The	   heat	  map	   shows	  the	   correlation	   between	   the	   expression	   of	   each	  module’s	   eigengene	   and	   experimental	  condition;	  cells	  show	  correlation	  coefficient	  (top)	  and	  corresponding	  P-­‐value	  (bottom).	  Cells	   are	   color-­‐coded	   using	   correlation	   values	   according	   to	   scale	   on	   the	   right.	   For	   the	  Vallat	  et	  al	  study;	  US	  =	  no	  stimulation	  and	  S	  =	  anti-­‐IgM	  stimulated.	  Time	  of	  stimulation	  (60,	   90,	   210	   and	   390	  minutes)	   is	   indicated.	   For	   the	   Herishanu	   et	   al	   study,	   source	   of	  sample	   is	   shown;	   peripheral	   blood	   (PB),	   bone	   marrow	   (BM),	   lymph	   node	   (LN).	   (B)	  Correlations	  between	  kME	  and	   fold	  difference	   in	  expression	  between	  LN	  compared	   to	  other	  sites	  (top)	  and	  following	  anti-­‐IgM	  stimulation	  in	  vitro	  (bottom)	  for	  the	  344	  genes	  comprising	   the	  blue	  module.	   (C)	   “TreeMap”	  view	  of	  over-­‐represented	  GO	   terms	   in	   the	  blue	  module,	  generated	  using	  REVIGO.	  Each	  rectangle	  represents	  a	  cluster	  of	  related	  GO	  terms.	   The	   representatives	   are	   joined	   into	   “superclusters”	   of	   loosely	   related	   terms,	  visualized	   with	   different	   colours.	   Size	   of	   the	   rectangles	   reflects	   Benjamini-­‐Hochberg	  adjusted	  p-­‐values.	  	  
Figure	  2.	  Effect	  of	  anti-­‐IgM	  on	  mRNA	  translation	  in	  CLL	  cells	  (A)	   Signaling	   responsive	   CLL	   samples	   (n=21)	   were	   incubated	  with	   anti-­‐IgM	   beads	   or	  control	   beads,	   or	   left	   untreated	   as	   a	   control	   for	   24	   hours.	   mRNA	   translation	   was	  analyzed	  by	  quantifying	  metabolic	   labeling.	   (B)	  As	   in	   (A),	  except	  cells	  were	  pretreated	  for	   1	   hour	   with	   ibrutinib	   (n=5)	   or	   tamatinib	   (n=4),	   or	   DMSO	   as	   a	   control,	   prior	   to	  addition	  of	  anti-­‐IgM	  or	  control	  beads.	  Graphs	  show	   fold	   increase	   in	  metabolic	   labeling	  (means	  ±SEM)	   compared	   to	   untreated	   cells	   (set	   to	   1.0).	   (C,D)	   Immunoblot	   analysis	   of	  phosphorylated/total	   p70S6K	   and	   ERK1/2	   expression	   at	   30	  minutes	   post-­‐stimulation	  with	  anti-­‐IgM	  beads	   (ibrutinib,	  n=6;	   tamatinib,	  n=5).	   (C)	  Representative	   immunoblots.	  (D)	   Quantitation	   of	   multiple	   experiments	   following	   30	   minutes	   stimulation;	   graphs	  show	  normalized	   p70S6K/ERK1/2	   phosphorylation	   (means	  ±SEM)	   as	   a	   percentage	   of	  control	   (DMSO)	   anti-­‐IgM-­‐treated	   cells.	   Statistical	   comparisons	   between	   groups	   are	  shown	  (Student’s	  t-­‐test).	  	  
Figure	  3.	  Analysis	  of	  mRNA	  translation	  using	  OPP-­‐labeling	  	  (A)	  Overview	  of	  experimental	  procedure	  for	  OPP-­‐labeling.	  (B)	  CLL	  samples	  (n=13)	  were	  treated	  with	   soluble	   anti-­‐IgM	   or	   anti-­‐IgM	   beads,	   control	   antibodies,	   CpG-­‐ODN2006	   or	  left	   untreated	   for	   24	   hours	   prior	   to	   OPP-­‐labeling.	   Graphs	   show	   fold	   increase	   in	   OPP-­‐labeling	   (means	   ±SEM)	   in	   CLL	   (CD19+CD5+)	   and	   T	   cells	   (CD19-­‐CD5+)	   with	   values	   for	  untreated	   CLL	   cells	   set	   to	   1.0.	   Statistical	   comparisons	   between	   untreated	   CLL	   and	   T	  cells,	   and	  between	  control	  and	  anti-­‐IgM	   treated	  CLL	  cells	  are	  shown	  (Student’s	   t-­‐test).	  (C,D)	  As	  in	  (B),	  except	  cells	  were	  pretreated	  for	  1	  hour	  with	  ibrutinib	  (n=5)	  or	  tamatinib	  (n=5),	   or	   DMSO	   as	   a	   control,	   prior	   to	   addition	   of	   anti-­‐IgM/control	   antibodies.	   Graphs	  show	  fold	  increase	  in	  OPP-­‐labeling	  (means	  ±SEM)	  for	  T	  cells	  (C)	  and	  CLL	  cells	  (D)	  with	  values	  for	  untreated	  cells	  set	  to	  1.0.	  Statistical	  comparisons	  between	  groups	  are	  shown	  (Student’s	  t-­‐test).	  	  	  
Figure	  4.	  Effect	  of	  anti-­‐IgM	  on	  eIF	  expression	  and	  comparison	  to	  normal	  B	  cells	  (A,B)	   CLL	   samples	   (n=12)	  were	   stimulated	  with	   anti-­‐IgM	   beads,	   control	   beads	   or	   left	  untreated.	   After	   24	   hours,	   expression	   of	   eIF4A,	   eIF4GI,	   eIF3B,	   PDCD4	   and	   HSC70	  (loading	  control)	  was	  analyzed	  by	  immunoblotting.	  (A)	  Representative	  immunoblot.	  (B)	  Quantitation	   of	   multiple	   experiments;	   graph	   shows	   normalized	   expression	   (means	  
16	  	  
±SEM)	   relative	   to	   control	   beads.	   	   Statistical	   comparisons	   between	   groups	   are	   shown	  (Student’s	  t-­‐test).	  (C)	  PBMCs	  from	  healthy	  donors	  (n=7)	  were	  treated	  with	  soluble	  anti-­‐IgM	  or	  anti-­‐IgM	  beads,	  control	  antibodies,	  CpG-­‐ODN2006	  or	  left	  untreated	  for	  24	  hours	  prior	   to	   OPP-­‐labeling.	   Graphs	   show	   fold	   increase	   in	   OPP-­‐labeling	   (means	   ±SEM)	   in	   B	  (CD19+CD5-­‐)	  and	  T	  cells	  (CD19-­‐CD5+)	  with	  values	  for	  untreated	  B	  cells	  set	  to	  1.0	  for	  each	  donor.	   Statistical	   comparisons	   between	   groups	   are	   shown	   (Student’s	   t-­‐test).	   (D,E)	  Normal	   B	   cells	   (n=5)	  were	   isolated	   from	  PBMCs	   by	   negative	   selection	   and	   stimulated	  with	   soluble	   anti-­‐IgM	  or	   control	   antibody,	   or	   left	  untreated	  as	   a	   control,	   for	  24	  hours.	  Expression	   of	   eIF4A,	   eIF4GI,	   eIF3B,	   PDCD4	   and	   HSC70	   were	   analyzed	   by	  immunoblotting.	   (D)	   Representative	   immunoblot.	   (E)	   Quantification	   of	   multiple	  experiments;	   graph	   shows	   normalized	   expression	   (means	   ±SEM)	   relative	   to	   control	  beads.	  	  Statistical	  comparisons	  between	  groups	  are	  shown	  (Student’s	  t-­‐test).	  
	  
Figure	  5.	  Anti-­‐IgM	  regulation	  of	  MYC	  mRNA	  transcription	  and	  translation	  	  CLL	   samples	   were	   pretreated	   for	   1	   hour	   with	   ibrutinib	   or	   tamatinib,	   or	   DMSO	   as	   a	  control,	   and	   then	   incubated	   with	   anti-­‐IgM	   or	   control	   beads	   for	   24	   hours.	   (A-­‐C)	  Monosome-­‐	   and	  polysome-­‐associated	  MYC	  mRNA	  was	  quantified	  using	  Q-­‐PCR;	  Graphs	  show	   total	   MYC	   mRNA	   (monosomal	   plus	   polysomal)	   (A),	   polysome-­‐associated	   MYC	  mRNA	   (B)	   and	   polysome/monosome	   ratio	   for	  MYC	   mRNA	   (C)	   for	   ibrutinb	   (n=5)	   and	  tamatinib	   (n=6).	   (D,E)	   MYC	   and	   β-­‐actin	   (loading	   control)	   protein	   analysis	   by	  immunoblotting.	   	   (D)	   Representative	   immunoblots	   and	   (E)	   quantitation	   of	   multiple	  experiments	   for	   4	   samples.	   Graphs	   show	  mean	   fold	   increases	   (±SEM)	  with	   values	   for	  anti-­‐IgM/DMSO-­‐treated	   cells	   set	   100%.	   Statistical	   comparisons	   between	   anti-­‐IgM/DMSO-­‐treated	  cells	  are	  shown	  (Student’s	  t-­‐test).	  
	  
	  
	  
	  
	  
